1. Home
  2. TPVG vs ALXO Comparison

TPVG vs ALXO Comparison

Compare TPVG & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriplePoint Venture Growth BDC Corp.

TPVG

TriplePoint Venture Growth BDC Corp.

HOLD

Current Price

$3.42

Market Cap

174.6M

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

SELL

Current Price

$1.06

Market Cap

172.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
TPVG
ALXO
Founded
2013
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
174.6M
172.8M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
TPVG
ALXO
Price
$3.42
$1.06
Analyst Decision
Hold
Strong Buy
Analyst Count
4
7
Target Price
★ $5.67
$4.60
AVG Volume (30 Days)
259.3K
★ 1.1M
Earning Date
11-04-2026
11-16-2026
Dividend Yield
★ 25.91%
N/A
EPS Growth
N/A
★ 26.36
EPS
★ 0.59
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.69
N/A
P/E Ratio
$6.02
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.51
$0.86
52 Week High
$6.95
$2.66

Technical Indicators

Market Signals
Indicator
TPVG
ALXO
Relative Strength Index (RSI) 21.34 44.18
Support Level N/A $1.03
Resistance Level $5.56 $1.34
Average True Range (ATR) 0.20 0.13
MACD -0.07 -0.00
Stochastic Oscillator 1.57 32.00

Price Performance

Historical Comparison
TPVG
ALXO

About TPVG TriplePoint Venture Growth BDC Corp.

TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the firm's operations are located across the United States.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: